MMRF News --
LOS ANGELES, CA, Sep 24, 2010 (MARKETWIRE via COMTEX) -- MMRGlobal, Inc.
(OTCBB: MMRF) (MMR) announced today that it has successfully opposed a Summary
Judgment Motion brought by the Lymphoma Researc h Foundation (LRF) as part of its
efforts to protect a portion of the Company's intellectual property, which it
previously disclosed on May 3, 2010.
The Company acquired the biotech assets from its reverse merger with Favrille,
Inc., a San Diego biotech company, in January 2009. Over the past year, MMR
identified a collection of these biotech assets, which include biotech samples
that were in the possession of the Lymphoma Research Foundation. They do not
include other pre-merger biotech assets, including the Company's anti-CD20
monoclonal antibodies, results of clinical trials data, patents and other
intellectual property.
According to declarations filed on behalf of MMR, the Company understands that
the biotech samples could have a value as high as $1.376 million. However, based
on other information currently maintained by the Company, the samples could have
a far greater value, depending on the extent and depth of the clinica l data
collected at trial initiation, the extent and depth of the clinical data
collected during patient follow-up, whether follow-up tissue samples are
available, and whether accompanying whole blood or serum is available from
patients from trial enrollment or during trial progression.
Robert H. Lorsch, Chairman and CEO of MMRGlobal, said, "We are pleased by this
early ruling. When combined with clinical data from the Company's vaccine
research into the causes and potential treatment of B-Cell Non-Hodgkin's
Lymphoma, including data from patient follow-ups which the Company has, the
value could be significant."
The Company understands its intellectual properties may also be of value in a
possible reinterpretation of the pre-merger Favrille vaccine trials and that the
IP may also unlock ways to create other "custom-made" cancer vaccines and be
valuable in discovering additional opportunities in cancer research. The Company
hop es to enter into licensing agreements with biopharmaceutical companies,
academic institutions, research organizations and others regarding the use of
its assets.
About MMRGlobal, Inc. MMR Global, Inc., through its wholly-owned operating
subsidiary, MyMedicalRecords, Inc. ("MMR"), provides secure and easy-to-use
online Personal Health Records ("PHRs") and electronic safe deposit box storage
solutions, serving consumers, healthcare professionals, employers, insurance
companies, financial institutions, and professional organizations and affinity
groups. MyMedicalRecords enables individuals and families to access their
medical records and other important documents, such as birth certificates,
passports, insurance policies and wills, anytime from anywhere using the
Internet. The MyMedicalRecords Personal Health Record is built on proprietary,
patented technologies to allow documents, images and voicemail messages to be
transmitted and st ored in the system using a variety of methods, including fax,
phone, or file upload without relying on any specific electronic medical record
platform to populate a user's account. The Company's professional offering,
MMRPro, is designed to give physicians' offices an easy and cost-effective
solution to digitizing paper-based medical records and sharing them with
patients in real time through an integrated patient portal. MMR is an
Independent Software Vendor Partner with Kodak to deliver an integrated turnkey
EMR solution for healthcare professionals. MMR is also an integrated service
provider on Google Health. To learn more about MMR Global, Inc. and its
products, visit www.mmrglobal.com.
Forward-Looking Statements Statements in this press release that are not
strictly historical in nature constitute "forward-looking statements." Such
statements include, but are not limited to, statements regarding MMRGlobal,
Inc.'s assets includi ng but not limited to its primary Health IT businesses,
samples and data from vaccine and clinical trials, and anti-CD20 antibody
assets. Such forward-looking statements involve known and unknown risks,
uncertainties and other factors that may cause actual results to be materially
different from historical results or from any results expressed or implied by
such forward-looking statements. These factors include, but are not limited to,
risks and uncertainties related to the development and approval of
biotechnology/biopharmaceutical product candidates and Health IT products and
additional risks discussed in the Company's filings with the Securities and
Exchange Commission. All subsequent written and oral forward-looking statements
attributable to the Company (or any person acting on the Company's behalf) are
qualified by the cautionary statements in this notice. MMRGlobal, Inc. is
providing this information as of the date of this release a nd, except as
required by law, does not undertake any obligation to update any forward-looking
statements contained in this release as a result of new information.
CONTACT:
Michael Selsman
Public Communications Co.
(310) 553-5732
ms@publiccommunications.biz
SOURCE: MMRGlobal, Inc.
CONTACT: mailto:ms@publiccommunications.biz
Copyright 2010 Marketwire, Inc., All rights reserved.
-0-
SUBJECT CODE: Computers and Software:Internet
Financial Services:Insurance
Medical and Healthcare:Facilities and Providers
Professional Services: General
Pharmaceuticals and Biotech:Biotech
Pharmaceuticals and Biotech:Trials
Medical and Healthcare:Healthcare
